VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Stephenson on the Development of Biomarkers for Prostate Cancer

Andrew J. Stephenson, MD
Published: Monday, Aug 21, 2017



Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.

It is important to develop tools to predict how patients are going to react to treatments, explains Stephenson. This can help the patient’s quality of life and equip them with the knowledge to make a well-informed decision regarding their treatment. Additionally, this can lead to higher rates of patient satisfaction, states Stephenson.
 


Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.

It is important to develop tools to predict how patients are going to react to treatments, explains Stephenson. This can help the patient’s quality of life and equip them with the knowledge to make a well-informed decision regarding their treatment. Additionally, this can lead to higher rates of patient satisfaction, states Stephenson.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x